February 2021

Celcuity Completes $24M Public Offering

United States - Minnesota

Celcuity, a clinical stage biotechnology company translating discoveries of new cancer sub-types into third-generation diagnostics and expanded therapeutic options for cancer patients, completed a $24 million public offering underwritten by Craig-Hallum. Faegre Drinker advised Craig-Hallum in the transaction and previously represented the underwriters in Celcuity’s IPO.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.